Leukemia
Return to Library
Studies from St. Jude Children's Research Hospital, Department of Oncology have provided new information about leukemia in children
2009 AUG 24 - (NewsRx.com) -- Researchers detail in 'Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1,' new data in leukemia. According to recent research from the United States, "To evaluate the impact of contemporary therapy on the clinical outcome of children with pre-B acute lymphoblastic leukemia (ALL) and the t(1;19)/TCF3/PBX1, we analyzed 735 patients with B-cell precursor ALL treated in four successive protocols at St Jude Children's Research Hospital. The 41 patients with the t(1;19) had a comparable event-free survival to that of the 694 patients with other B-cell precursor ALL (p=0.63; 84.2±7.1% (s.e.) vs 84.0±1.8% at 5 years)." "However, patients with the t(1;19) had a lower cumulative incidence of any hematological relapse (p=0.06; 0 vs 8.3±1.2% at 5 years) but a significantly higher incidence of central nervous system (CNS) relapse (p <0.001; 9.0±5.1% vs 1.0±0.4% at 5 years). In a multivariate analysis, the t(1;19) was an independent risk factor for isolated CNS relapse," wrote S. Jeha and colleagues, St. Jude Children's Research Hospital, Department of Oncology. The researchers concluded: "These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse." Jeha and colleagues published their study in Leukemia (Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia, 2009;23(8):1406-9). For additional information, contact S. Jeha, St. Jude Children's Research Hospital, Dept. of Oncology, Memphis, TN 38105 USA.. Publisher contact information for the journal Leukemia is: Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA. Keywords: United States, Memphis, Acute Lymphoblastic Leukemia, B-Cell Leukemia, Hematology, Oncology, Pediatrics, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
